Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Clovis Oncology, Inc.
This is a randomised, multinational, double blind, dual placebo controlled, 4-arm study of Rucaparib and Nivolumab. Oral Rucaparib and the oral placebo drug will be administered twice daily. Intravenous Nivolumab and intravenous placebo will be administered once every four weeks.